SCHEMBL4280669

SCHEMBL4280669

O=C(O)C[C@H](NC(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.67

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 19/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4280674 1.00 CASP1 (0.67) CASP1
SCHEMBL732093 0.92 CASP1 (0.66) CASP1
SCHEMBL7166866 0.92 CASP1 (0.66) CASP1
SCHEMBL8085967 0.92 CASP1 (0.66) CASP1
SCHEMBL6261373 0.91 CASP1 (0.62) CASP1
SCHEMBL28968911 0.91 CASP1 (0.62) CASP1
SCHEMBL13724740 0.91 CASP1 (0.64) CASP1
SCHEMBL19695419 0.91 CASP1 (0.64) CASP1
SCHEMBL1067460 0.91 CASP1 (0.64) CASP1
SCHEMBL376886 0.91 CASP1 (0.67) CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0624599-B1 Derivatives of mono (6-amino-desoxy)cyclodextrin substituted in position 6 with an alpha aminoacid group, process of their preparation and applications OREAL (FR) 1997-07-30 EP claimed
JP-2036162-A None JP disclosed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 EP disclosed
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2025-11-18 US disclosed
WO-2025106386-A1 A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-22 WO disclosed
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-15 US disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 US disclosed
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-11-19 US disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 EP disclosed
EP-4406606-A2 ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE G Bayer Pharma Aktiengesellschaft (DE) 2024-07-31 EP disclosed
WO-1993013066-A1 CYCLIC AMIDES OF 3-AMINO-2-HYDROXY-CARBOXYLIC ACIDS AS HIV-PROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1993-07-08 WO disclosed
EP-0310341-B1 N-(L-ASPARTYL)AMINO ALCOHOL DERIVATIVES AND SWEETENER CONTAINING THE SAME Takasago International Corporation (JP) 1993-03-17 EP disclosed
EP-0438873-A1 Inhibitor of ribonucleotide reductase of herpes viruses MERCK & CO. INC. (US) 1991-07-31 EP disclosed
CN-1044467-A L-aspartyl-L-Ala, Serine and glycine dipeptide ester and acid amides sweeting agent simple substance or mixture and preparation method ZENG GUANGZHI (CN) 1990-08-08 CN disclosed
JP-H0236162-A N-(L-ASPARTYL)AMINOALCOHOL DERIVATIVE AND SWEETENER CONTAINING SAID DERIVATIVE TAKASAGO INTERNATL CORP 1990-02-06 JP disclosed
EP-0310341-A2 N-(L-aspartyl)amino alcohol derivatives and sweetener containing the same Takasago International Corporation (JP) 1989-04-05 EP disclosed
EP-0279832-A1 ENZYMATIC PROCESS CELLTECH LIMITED (GB) 1988-08-31 EP disclosed
CN-86104131-A L-asparaginyl aminodipeptide sweetening agent and preparation method 1988-06-22 CN disclosed
WO-1988001650-A1 ENZYMATIC PROCESS CELLTECH LIMITED (GB) 1988-03-10 WO disclosed
EP-0127411-A2 Method of preparing alpha-l-aspartyl-l-phenylalanine methyl ester and its hydrochloride AJINOMOTO CO., INC. (JP) 1984-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 CASP1 1059/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B CASP1 4106/4885
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups KIFC1, KIF2C, KIF5B CASP1 1279/4885
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA IL1R1, IL1A, IL1B CASP1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.